Peginterferon alfa-2b
- Generic Name
- Peginterferon alfa-2b
- Brand Names
- Pegintron, Sylatron
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 215647-85-1
- Unique Ingredient Identifier
- G8RGG88B68
- Background
Peginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting...
- Indication
Peginterferon alfa-2b is indicated for the treatment of HCV in combination with Ribavirin and a NS3/4A protease inhibitor for genotype 1 or without a NS3/4A protease inhibitor for genotypes 2-6 . May be used as a monotherapy in patients with contraindications to or significant intolerance to other anti-viral therapies.
...
- Associated Conditions
- Chronic Hepatitis C Virus (HCV) Infection, Melanoma
- Associated Therapies
- -
Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and PEG-INTRON(R)
- Conditions
- Interventions
- First Posted Date
- 2006-12-25
- Last Posted Date
- 2018-08-21
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 5
- Registration Number
- NCT00415857
- Locations
- πΊπΈ
UT MD . Anderson Cancer Center, Houston, Texas, United States
Pegintron Induction Therapy in HCV Non-Responders
- Conditions
- First Posted Date
- 2006-08-15
- Last Posted Date
- 2006-08-15
- Lead Sponsor
- Foundation for Liver Research
- Target Recruit Count
- 110
- Registration Number
- NCT00363259
- Locations
- π³π±
Atrium Medisch Centrum, Heerlen, Netherlands
π³π±OLVG, Amsterdam, Netherlands
π³π±LUMC, Leiden, Netherlands
Viral Kinetic Study With Viramidine in Therapy-Naive Patients With Chronic Hepatitis C
- Conditions
- First Posted Date
- 2006-03-21
- Last Posted Date
- 2012-06-22
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT00305383
- Locations
- πΊπΈ
Maryland Digestive Disease Research, Laurel, Maryland, United States
πΊπΈSan Mateo Medical Center, San Mateo, California, United States
πΊπΈLiver Center of Long Island, Plainview, New York, United States
PegIntron Versus IntronA in CMAJCC Stage II (EADO 2001/CMII Trial)
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2010-10-13
- Lead Sponsor
- University Hospital, Bordeaux
- Target Recruit Count
- 898
- Registration Number
- NCT00221702
- Locations
- π«π·
APHM, dermatology, Marseille, France
Zidovudine Levels in HIV Infected Patients Being Treated for HCV
- Conditions
- Interventions
- First Posted Date
- 2003-04-24
- Last Posted Date
- 2009-08-07
- Target Recruit Count
- 16
- Registration Number
- NCT00059358
- Locations
- π΅π·
UPR Adult ACTU, San Juan, Puerto Rico
Safety, Tolerability, and Anti-HIV Activity of PEG-Intron in HIV-Positive Children
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 54
- Registration Number
- NCT00006325
- Locations
- πΊπΈ
Children's Hosp of Los Angeles/UCLA Med Ctr, Los Angeles, California, United States
πΊπΈLos Angeles County - USC Med Ctr, Los Angeles, California, United States
πΊπΈSUNY Health Sciences Ctr at Syracuse / Pediatrics, Syracuse, New York, United States
Safety and Effectiveness of PEG-Intron in HIV-Infected Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Schering-Plough
- Target Recruit Count
- 250
- Registration Number
- NCT00005012
- Locations
- πΊπΈ
East Bay AIDS Ctr, Berkeley, California, United States
πΊπΈUniv of Maryland Institute of Human Virology, Baltimore, Maryland, United States
πΊπΈMCP Hahnemann Univ, Philadelphia, Pennsylvania, United States
Interleukin-2 (IL-2), Pegylated Interferon (PEG-IFN Alfa-2b), and Ribavirin (RBV) Treatment in Patients With Hepatitis C and HIV Coinfection
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 24
- Registration Number
- NCT00015652
- Locations
- πΊπΈ
Northwestern University CRS, Chicago, Illinois, United States
πΊπΈJohns Hopkins Adult AIDS CRS, Baltimore, Maryland, United States
πΊπΈUCLA CARE Center CRS, Los Angeles, California, United States
Peginterferon Alpha-2b And Ribavirin to Treat Hepatitis C in HIV-Infected Patients
- Conditions
- Interventions
- First Posted Date
- 2001-06-28
- Last Posted Date
- 2014-10-01
- Target Recruit Count
- 36
- Registration Number
- NCT00018031
- Locations
- πΊπΈ
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.